6名分析师给予Zevra治疗师“Buy”评分,平均12个月目标价格为20.25美元。 6 analysts give Zevra Therapeutics a "Buy" rating with an average 12-month target price of $20.25.

Zevra治疗公司(Zevra Serecturetics)是一家针对严重医疗状况开发药物的公司, 获得6家分析公司一致的“Buy”评分, 平均12个月目标价格为20.25美元。 Zevra Therapeutics, a company developing prodrugs for serious medical conditions, has received a consensus "Buy" rating from 6 analyst firms with an average 12-month target price of $20.25. 其主要产品候选人KP1077IH和KP1077N分别处于第2阶段和第1个半临床试验阶段。 Its lead product candidates, KP1077IH and KP1077N, are in Phase 2 and Phase ½ clinical trials respectively. 机构投资者持有公司股票的35.03%,内幕人士在过去90天购买了22 000股股票。 Institutional investors hold 35.03% of the company's stock and insiders have bought 22,000 shares over the last 90 days.